Judge Stark issues claim constructions in AstraZeneca’s CRESTOR patent litigation

Posted byYoung Conaway StaffPosted inLeonard P. Stark, Chief Judge

On February 2, 2012, Judge Stark issued a Memorandum Opinion construing the following claim term of AstraZeneca’s U.S. Patent No. RE37,314 directed to novel compounds that inhibit the biosynthesis of cholesterol, including the active ingredient in CRESTOR®:

“a cation capable of forming a non-toxic pharmaceutically acceptable salt”
AstraZeneca UK Ltd. v. Watson Laboratories, Inc., C.A. No. 10-915-LPS (D. Del. Feb. 2, 2012). The Court agreed with defendant Watson Laboratories that “the specification provide[d] an express definition that limit[ed] the term … to an alkali metal ion, alkaline earth metal ion, or ammonium ion”


AstraZeneca UK Ltd. v. Watson Laboratories, Inc., C.A. No. 10-915-LPS (D. Del. Feb. 2, 2012)

(function() { var scribd = document.createElement(“script”); scribd.type = “text/javascript”; scribd.async = true; scribd.src = “https://www.scribd.com/javascripts/embed_code/inject.js”; var s = document.getElementsByTagName(“script”)[0]; s.parentNode.insertBefore(scribd, s); })();